Randomized Multicenter Trial of More Intense and Standard Early Verteporfin Treatment of Neovascular Age-Related Macular Degeneration

Overall outcomes regarding visual benefit, lesion anatomic features, and number of retreatments after 6 months were similar for patients receiving more intense or standard early therapy. An unplanned retrospective analysis showed that there was significantly less vision loss when the more intense regimen was used to treat smaller lesions.